Traditional Chinese Medicine Faces Clinical Trial Test for Long COVID Treatment

Can Traditional Medicine Revolutionize Long COVID Treatment?

Chinese researchers have launched an extensive multicenter clinical trial to evaluate the efficacy of Shenlingkangfu (SLKF) granules in treating lingering COVID-19 symptoms. The randomized, double-blind, placebo-controlled study will enroll 154 participants across ten clinical centers in China's Hunan province, with recruitment running from January 2024 through December 2025. The trial aims to provide evidence-based data on traditional Chinese medicine's role in addressing persistent post-COVID symptoms, particularly for patients with lung-spleen qi deficiency syndrome.

The study comes amid growing global concern over "long COVID," which affects an estimated 65 million people worldwide according to World Health Organization statistics. Long-term symptoms—including fatigue, cognitive issues, respiratory problems, and pain—can persist for months after initial infection, significantly impacting patients' quality of life. Current pharmaceutical interventions like Paxlovid (nirmatrelvir-ritonavir) have shown some preventive effect against convalescent COVID-19, but safety concerns remain, creating an opportunity for alternative approaches.

What Mechanisms Support SLKF’s Impact on Long COVID?

SLKF granules contain 14 traditional Chinese medicinal ingredients, including Astragali Radix, Poria, and Codonopsis Radix, which are believed to supplement the body's qi (vital energy). Modern pharmacological studies suggest these components may inhibit pro-inflammatory cytokines including IL-6 and TNF-α, potentially addressing underlying mechanisms of long COVID. "This formula targets multiple pathways simultaneously," explained Dr. Jinwen Ge, one of the study's principal investigators. "Preliminary evidence indicates these herbal components may help regulate immune response and repair tissue damage persisting after acute COVID infection."

The trial's primary outcome will measure the therapeutic effective rate of SLKF granules at three months and assess total clinical symptom scores. Secondary outcomes include improvements in fatigue, pain, sleep quality, cognitive function, anxiety, and depression, alongside changes in inflammatory markers like C-reactive protein and interleukin-6. Participants will receive either SLKF granules or a placebo for one month, followed by two months of follow-up assessment. All will receive health management guidance, including recommendations for personal hygiene, balanced nutrition, moderate exercise, and adequate rest.

The research protocol follows the Standard Protocol Items: Recommendations for Interventional Trials Traditional Chinese Medicine (SPIRIT-TCM) Extension 2018 Statement checklist, ensuring methodological rigor. Eligible participants must have confirmed or physician-suspected SARS-CoV-2 infection at least six months prior, meet diagnostic criteria for convalescent COVID-19, and demonstrate lung-spleen qi deficiency syndrome according to TCM diagnostic criteria. The study employs a comprehensive assessment of symptom improvement using validated scales including the Fatigue Self-Assessment Scale (FAS), Pain Visual Analog Scale (VAS), Pittsburgh Sleep Quality Index (PSQI), Mini-Mental State Examination (MMSE), and Hospital Anxiety and Depression Scale (HADS).

Is Modern Research Embracing Holistic Approaches?

This research represents a growing trend in the pharmaceutical industry to investigate traditional medicines using rigorous clinical trial methodologies. While conventional pharmaceutical companies have primarily focused on antiviral treatments and vaccines, there's increasing interest in addressing the persistent symptoms of COVID-19. Unlike the targeted approach of most Western pharmaceuticals, traditional Chinese medicine typically employs multi-component formulations designed to restore overall balance within body systems. "The advantage of TCM lies in its holistic approach to recovery," noted Dr. Le Xie, a supervisor on the project. "Rather than targeting single symptoms, these formulations aim to strengthen the body's inherent recovery mechanisms."

The industry implications extend beyond COVID-19 treatment. As pharmaceutical companies struggle with high development costs and lengthy approval processes for single-molecule drugs, some are exploring partnerships with traditional medicine researchers to identify novel therapeutic approaches. Several major pharmaceutical corporations have established natural product research divisions or collaborations with institutions specializing in traditional medicines. This trial could potentially validate a complementary approach to managing post-viral syndromes, creating opportunities for hybrid therapeutic strategies.

Are Safety and Regulatory Hurdles a Barrier to Traditional Formulations?

Safety evaluations are a critical component of the study design. Researchers will monitor adverse events and conduct comprehensive laboratory assessments including blood, urine, and stool tests, liver and kidney function tests, and electrocardiograms at baseline, one month, and three months. The investigators acknowledge that while the traditional formula has a history of use in respiratory conditions, standardized safety data is essential for broader acceptance within modern healthcare frameworks.

Despite growing interest, significant challenges remain in bringing traditional formulations to global markets, including standardization issues, quality control, and regulatory hurdles. The researchers acknowledge these limitations, noting that "this trial remains an exploratory study, with deficiencies in the diagnosis of study subjects, sample size, treatment duration, and selection of outcome measures." They emphasize that larger studies with extended observation periods will be necessary to fully establish the efficacy and safety profile of SLKF granules.

Industry Context: This clinical trial reflects the pharmaceutical industry's expanding interest in evidence-based traditional medicines as complementary approaches to conventional drug development. As COVID-19 transitions from acute crisis to chronic health challenge, companies are increasingly exploring multi-modal treatment strategies that address persistent symptoms and quality-of-life issues. The study also highlights the growing acceptance of rigorous clinical evaluation methods for traditional formulations, potentially creating new partnership opportunities between conventional pharmaceutical companies and traditional medicine researchers in addressing the substantial unmet need for effective long COVID interventions.

Summary

Chinese researchers have initiated a comprehensive multicenter clinical trial to evaluate Shenlingkangfu (SLKF) granules, a traditional Chinese medicine formulation, for treating long COVID symptoms. The randomized, double-blind, placebo-controlled study will enroll 154 participants across ten clinical centers in Hunan province, China, with recruitment extending from January 2024 through December 2025. The trial specifically targets patients experiencing persistent post-COVID symptoms associated with lung-spleen qi deficiency syndrome, addressing a global health concern affecting an estimated 65 million people worldwide. SLKF granules contain 14 traditional medicinal ingredients, including Astragali Radix, Poria, and Codonopsis Radix, which modern pharmacological research suggests may inhibit pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha. The study will measure therapeutic effectiveness at three months using comprehensive assessments of fatigue, pain, sleep quality, cognitive function, anxiety, depression, and inflammatory markers. This research represents a significant trend in pharmaceutical development, as the industry increasingly investigates traditional medicines using rigorous clinical methodologies to address the persistent symptoms of COVID-19 and other post-viral syndromes. The trial follows international standards for traditional Chinese medicine research and includes comprehensive safety evaluations, though researchers acknowledge limitations regarding sample size, treatment duration, and diagnostic criteria that will require larger follow-up studies for definitive conclusions.